Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 17/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 17/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 17/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | TPH1 | P17752 | 1/20 | 0.43 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5322444 | 0.83 | GABBR2 (0.49) | CYP2D6 | |
| SCHEMBL839944 | 0.82 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL5320805 | 0.82 | UGT2B7 (0.49) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL12320565 | 0.81 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL31165823 | 0.79 | KMT2A (0.55) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL5720949 | 0.79 | KMT2A (0.55) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL21690086 | 0.79 | KMT2A (0.55) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL5720938 | 0.79 | KMT2A (0.55) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL5323449 | 0.78 | CYP26A1 (0.43) | — | |
| SCHEMBL12278973 | 0.78 | UGT2B7 (0.50) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070258899-A1 | Diagnostic and therapeutic agents | KARYON-CTT LTD (FI) | 2007-11-08 | — | — | US | disclosed |
| WO-2007113385-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2007-10-11 | — | — | WO | disclosed |
| US-6833366-B1 | Dihydrostilbene alkanoic acid derivatives | PHARMACIA CORPORATION | 2004-12-21 | — | — | US | disclosed |
| US-6720315-B2 | FOR INHIBITING BONE RESORPTION, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR METASTASIS, SOLID TUMOR GROWTH, ANGIOGENESIS, MACULAR DEGENERATION AND DIABETIC RETINOPATHY RETINOPATHY | PHARMACIA CORPORATION | 2004-04-13 | — | — | US | disclosed |
| EP-1289959-A1 | DIHYDROSTILBENE ALKANOIC ACID DERIVATIVES USEFUL AS VITRONECTIN ANTAGONISTS | Pharmacia Corporation (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020099209-A1 | Dihydrostilbene alkanoic acid derivatives | PHARMACIA CORPORATION | 2002-07-25 | — | — | US | disclosed |
| WO-2001096310-A1 | DIHYDROSTILBENE ALKANOIC ACID DERIVATIVES USEFUL AS VITRONECTIN ANTAGONISTS | PHARMACIA CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258899-A1 | Diagnostic and therapeutic agents | YBX1, MLX, TPX2 | SLC6A2 3882/4885SLC6A4 3604/4885SLC6A3 4225/4885 |
| US-20020099209-A1 | Dihydrostilbene alkanoic acid derivatives | ITGA5, ITGB5, ITGB1 | SLC6A2 2455/4885SLC6A4 2495/4885SLC6A3 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.